Syneos Health Signs Agreement With Aotearoa Clinical Trials, Further Expanding Catalyst Site Program In New Zealand
Portfolio Pulse from Happy Mohamed
Syneos Health (NASDAQ:SYNH) has signed an agreement with Aotearoa Clinical Trials to expand its clinical trial capabilities in New Zealand. Aotearoa Clinical Trials will join the Syneos Health Catalyst Site Program, which aims to strengthen collaborations with clinical research sites worldwide. The partnership will enable sites, sponsors, and patients to collaborate in multiple therapeutic areas.
August 10, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syneos Health's partnership with Aotearoa Clinical Trials will expand its clinical trial capabilities in New Zealand, potentially leading to increased business opportunities.
The partnership with Aotearoa Clinical Trials allows Syneos Health to expand its clinical trial capabilities in New Zealand. This could lead to increased business opportunities and potentially boost its revenues, which could have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100